We offer several options to help cover the cost of Tarceva® (erlotinib) tablets for your patients who are uninsured, have been denied coverage by their health plans, have concerns about co-pays or are worried about out-of-pocket expenses.
Genentech offers the Genentech BioOncology Co-pay Card to help qualified patients with the out-of-pocket costs associated with their Tarceva prescription.
If privately or publicly insured patients have difficulty paying for their Tarceva co-pay, co-insurance or other expenses, Tarceva Access Solutions can refer them to a co-pay assistance foundation* supporting their disease state.
GATCF was established to help patients with unmet medical needs who are uninsured or rendered uninsured by payer denial and who meet specific financial and medical criteria to receive Tarceva free of charge. Learn more
|*||Genentech and Astellas Pharmaceuticals do not influence or control the operations of these co-pay assistance foundations, but Tarceva Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by Tarceva Access Solutions. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.|